ZURICH--(BUSINESS WIRE)--Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, today announced data showing both single and repeated ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
Genfit (NASDAQ:GNFT) saw its stock decline 9% following the company’s announcement to discontinue its VS-01 therapy for Acute-on-Chronic Liver Failure (ACLF). The decision came after a safety incident ...
Genfit SA is discontinuing its VS-01 program in acute-on-chronic liver failure (ACLF), and has decided to reprioritize development of VS-01 for urea cycle disorder.
Genfit has stopped development of VS-01 in acute-on-chronic liver failure (ACLF) after a patient suffered a serious adverse event in a phase 2 trial. The French drugmaker acquired VS-01 when it bought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results